Effects of Age and Obesity on Brain Insulin Sensitivity
Launched by UNIVERSITY HOSPITAL TUEBINGEN · Apr 29, 2020
Trial Information
Current as of April 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Body-Mass Index (BMI) between 19-35 kg/m2
- • HbA1c ≤6.0%
- • normal glucose tolerance during 75g oral glucose tolerance test (OGTT)
- Exclusion Criteria:
- • Not removable metal parts in or on the body
- • manifest cardiovascular disease
- • claustrophobia
- • recent surgery (less than 3 months)
- • Simultaneous participation in other studies
- • Acute disease or infection within the last 4 weeks
- • neurological and psychiatric disorders
- • treatment with centrally acting drugs
- • hemoglobin Hb \<13g / dl
- • Hypersensitivity to any of the substances used
About University Hospital Tuebingen
University Hospital Tübingen is a leading academic medical institution in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its multidisciplinary expertise and cutting-edge facilities to develop new therapeutic strategies and improve patient outcomes. With a strong focus on translational medicine, University Hospital Tübingen collaborates with various stakeholders, including pharmaceutical companies and research organizations, to facilitate the efficient and ethical conduct of trials across a wide range of medical disciplines. Their dedication to patient-centered research and rigorous scientific standards positions them at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tübingen, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
